345 related articles for article (PubMed ID: 12610718)
21. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.
Bervoets C; Morrens M; Vansteelandt K; Kok F; de Patoul A; Halkin V; Pitsi D; Constant E; Peuskens J; Sabbe B
CNS Drugs; 2012 Nov; 26(11):975-82. PubMed ID: 23018547
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
Fleischhacker WW; Sanchez R; Johnson B; Jin N; Forbes RA; McQuade R; Baker RA; Carson W; Kane JM
Int Clin Psychopharmacol; 2013 Jul; 28(4):171-6. PubMed ID: 23615694
[TBL] [Abstract][Full Text] [Related]
24. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.
De Deyn P; Jeste DV; Swanink R; Kostic D; Breder C; Carson WH; Iwamoto T
J Clin Psychopharmacol; 2005 Oct; 25(5):463-7. PubMed ID: 16160622
[TBL] [Abstract][Full Text] [Related]
25. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Weiden PJ; Citrome L; Alva G; Brams M; Glick ID; Jackson R; Mattingly G; Kianifard F; Meng X; Pestreich L; Hochfeld M; Winseck A
Schizophr Res; 2014 Mar; 153(1-3):160-8. PubMed ID: 24529610
[TBL] [Abstract][Full Text] [Related]
26. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
27. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
Pigott TA; Carson WH; Saha AR; Torbeyns AF; Stock EG; Ingenito GG;
J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
[TBL] [Abstract][Full Text] [Related]
28. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
[TBL] [Abstract][Full Text] [Related]
30. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
31. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.
Adams DH; Kinon BJ; Baygani S; Millen BA; Velona I; Kollack-Walker S; Walling DP
BMC Psychiatry; 2013 May; 13():143. PubMed ID: 23694720
[TBL] [Abstract][Full Text] [Related]
32. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
33. Aripiprazole: in adolescents with schizophrenia.
Sanford M; Keating GM
Paediatr Drugs; 2007; 9(6):419-23. PubMed ID: 18052412
[TBL] [Abstract][Full Text] [Related]
34. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study.
Andrezina R; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; McQuade RD
Curr Med Res Opin; 2006 Nov; 22(11):2209-19. PubMed ID: 17076982
[TBL] [Abstract][Full Text] [Related]
35. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
36. Trial of aripiprazole in the treatment of first-episode schizophrenia.
Lee HY; Ham BJ; Kang RH; Paik JW; Hahn SW; Lee MS; Lee MS
Psychiatry Clin Neurosci; 2010 Feb; 64(1):38-43. PubMed ID: 20416024
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
[TBL] [Abstract][Full Text] [Related]
38. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
[TBL] [Abstract][Full Text] [Related]
39. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A
Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576
[TBL] [Abstract][Full Text] [Related]
40. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study.
Findling RL; Kauffman RE; Sallee FR; Carson WH; Nyilas M; Mallikaarjun S; Shoaf SE; Forbes RA; Boulton DW; Pikalov A
J Clin Psychopharmacol; 2008 Aug; 28(4):441-6. PubMed ID: 18626272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
